#### 1 Causal Evaluation of Laboratory Markers in Type 2 Diabetes on Cancer and Vascular Diseases

#### 2 Using Various Mendelian Randomization Tools

- 3 Heejin Jin<sup>1,2</sup>, Sanghun Lee<sup>3\*</sup>, Sungho Won<sup>1,4,5\*</sup>
- 4
- <sup>5</sup> <sup>1</sup>Department of Public Health Sciences, Seoul National University, Seoul, Republic of Korea
- <sup>6</sup> <sup>2</sup>Medical Research Collaborating Center, Department of Biostatistics, Seoul National University
- 7 Boramae Hospital, Seoul, Republic of Korea
- <sup>3</sup>Department of Medical Consilience, Graduate School, Dankook University, Yongin-si, Republic of
   Korea
- <sup>4</sup>Institute of Health and Environment, Seoul National University, Seoul, South Korea
- <sup>5</sup>RexSoft Corp, Seoul, South Korea
- 12

#### 13 Abstract

14 Multiple studies have demonstrated the effects of type 2 diabetes (T2D) on various human diseases; however, most of these were observational epidemiological studies that suffered from many potential 15 biases including reported confounding and reverse causations. In this article, we investigated whether 16 17 cancer and vascular disease can be affected by T2D-related traits, including fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2h-PG), and glycated hemoglobin A1c (HbA1c) levels, by 18 19 using Mendelian randomization (MR). The summary statistics for FPG, 2h-PG, and HbA1c were 20 obtained through meta-analyses of large-scale genome-wide association studies that included data 21 from 133,010 non-diabetic individuals from collaborating Meta-Analysis of Glucose and Insulin 22 related traits Consortium studies. Thereafter, based on the statistical assumptions for MR analyses, 23 the most reliable approaches including inverse-variance-weighted (IVW), MR-Egger, MR-Egger 24 with a simulation extrapolation (SIMEX), weighted median and MR-Pleiotropy RESidual Sum and 25 Outlier (MR-PRESSO) methods were applied to identify traits affected by FPG, 2h-PG, and HbAlc. We found that coronary artery disease is affected by FPG, as per the IVW [log odds ratio (logOR): 26 27 0.21; P=0.012], MR-Egger (SIMEX) (logOR: 0.22; P=0.014), MR-PRESSO (logOR: 0.18; 28 P=0.045), and weighted median (logOR: 0.29; P<0.001) methods, but not as per the MR-Egger 29 (logOR: 0.13; P=0.426) approach. Furthermore, low-density lipoprotein cholesterol levels are 30 affected by HbA1c, as per the IVW (beta (B): 0.23; P=0.015), MR-Egger (B: 0.45; P=0.046), MR-31 Egger (SIMEX) (B: 0.27; P=0.007), MR-PRESSO (B; 0.14; P=0.010), and the weighted median (B: 0.15; P=0.012) methods. Further studies of the associated biological mechanisms are required to 32 33 validate and understand the disease-specific differences identified in the TD2-related causal effects of 34 each trait.

35

#### 36 1 Introduction

- 37 Type 2 diabetes (T2D) is characterized by high blood sugar, insulin resistance, and a relative lack of
- insulin and represents a common metabolic disorder worldwide. In its early stage, T2D is easy to
- 39 ignore due to the lack of symptoms; however, chronic or poorly controlled T2D leads to eventually
- 40 disabling or life-threatening complications. Numerous epidemiological studies have consistently
- 41 demonstrated increased risks of cancer, vascular disease, nerve damage, and poor health-related
- 42 outcomes in T2D patients (De Vegt et al., 1999;Laakso, 1999;Tsilidis et al., 2015), resulting in a
- 43 shorter life expectancy (Collaboration, 2011). The main T2D-related complications reported in large-
- 44 scale epidemiological studies tend to be malignant solid tumors (Johnson et al., 2012) and
- 45 cardiovascular disease, including ischemic heart disease and stroke (Nesto, 2001;Bax et al.,
- 46 2007; Gleissner et al., 2007; Young et al., 2009). However, the causal relationship between T2D and
- 47 diverse health-related outcomes needs to be investigated and compared.
- 48 Fasting plasma glucose (FPG) levels  $\geq$  126 mg/dL or post-challenge 2-h plasma glucose (2h-PG)
- 49 levels  $\geq$  200 mg/dL in a 75-g 2-h oral glucose tolerance test (2h-OGTT) have been used as diagnostic
- 50 criteria for T2D. Additionally, hemoglobin A1c (HbA1c) levels  $\geq 6.5\%$  were added to these
- 51 diagnostic criteria in 2010 (Gavin III et al., 1997;Association, 2010). The three tests (FPG, 2h-PG,
- 52 and HbA1c) are dependent on blood glucose metabolism status. Specifically, FPG assesses the state
- of stable sugar levels in the body following a temporary increase in externally administered sugar.
- 54 The 2h-OGTT indicates how efficiently insulin is processed during metabolism in response to
- 55 increased externally administered glucose. HbA1c reflects the average blood sugar level until
- 56 immediately before the test and not at the time of sample collection, because hemoglobin increases
- 57 with time and according to glucose concentration (Nathan et al., 2007;Nathan et al., 2008).
- 58 Therefore, it is necessary to investigate the causal effects of these three T2D-related traits in the
- 59 blood and how they differ in subsequent pathological disorders.
- 60 To efficiently identify causal associations between T2D-related traits and various phenotypes without
- 61 potential biases or confounding and/or reverse causations, Mendelian randomization (MR) can be
- 62 used to assess how genetic variants act as instruments for instrumental variable (IV) analysis aimed
- at estimating the causal effect of one trait on another. Using genetic variants as instruments, which
- are not associated with conventional confounders of observational studies, allows the MR approach
- 65 to be considered analogous to randomized controlled trials (Burgess and Thompson, 2015). MR
- analysis requires three assumptions: 1) IVs are strongly associated with intermediate exposure, 2) IVs
   are independent of confounders, and 3) IVs affect outcomes only through the exposure path. If these
- are independent of confounders, and 3) is a free outcomes only infough the exposure path. If these assumptions hold, an inverse-variance-weighted (IVW) method provides the most efficient and
- 69 unbiased estimates of causal effects (Burgess et al., 2020). Various MR methods have been proposed
- 70 for providing a more robust approach under weaker assumptions (Burgess et al., 2013;Bowden et al.,
- 71 2015;Bowden et al., 2016a;Bowden et al., 2016b;Verbanck et al., 2018).
- 72 The aim of this study was to assess the causal effect of T2D-related traits (FPG, 2h-PG, and HbA1c)
- on cancers and vascular diseases via MR analysis using several methods, including those measuring
   sensitivity in the MR-Base platform database (Hemani et al., 2016).

#### 75 2 Materials and Methods

#### 76 **2.1 Exposure datasets**

The exposure traits of interest were FPG, 2h-PG, and HbA1c. The summary statistics for T2D-related
 traits were obtained through large-scale genome-wide association study (GWAS) meta-analyses of

79 133,010 non-diabetic individuals from collaborating studies within the Meta-Analysis of Glucose and

- 80 Insulin related traits Consortium (MAGIC) (Scott et al., 2012). In most of these studies, participants
- 81 were of European ancestry and adults. A total of  $\sim 2.5$  million genome-wide directly genotyped or
- imputed autosomal single-nucleotide polymorphisms (SNPs) were reported, including 36, 9, and 11 SNPs with genome-wide significant ( $P < 5 \times 10^{-8}$ ) associations with FPG, 2h-PG, and HbA1c,
- explaining 4.8%, 1.7%, and 2.4% of the variance in the trait, respectively. Among these, SNPs were
- explaining 4.3%, 1.7%, and 2.4% of the variance in the trait, respectively. Allong these, SIVFS were selected as IV candidates not in linkage disequilibrium (LD;  $r^2 < 0.001$ ) or within 10,000 kb of an
- 86 established signal. To specify final IV sets, available genetic instruments for assessing outcome traits
- 87 of interest were explored via the MR-Base platform database (https://www.mrbase.org/) or through
- the R package 'TwoSampleMR' (https://rdrr.io/github/MRCIEU/TwoSampleMR/). To reflect the
- same reference strand between exposure and outcome, alleles and effects were harmonized using
- 90 effect/non-effect alleles and minor allele frequency for palindromic SNPs.

#### 91 2.2 Outcome datasets

- 92 Human phenotypes were divided into two categories of diseases or traits known to be related to T2D.
- 93 The first category was cancer at major sites: breast, gall bladder, lung [adenocarcinoma and
- 94 squamous cell (SC) carcinoma], ovarian, pancreatic, and thyroid (differentiated types). The second
- 95 category was vascular disease: coronary kidney disease (CKD), coronary artery disease (CAD),
- 96 stroke, cardio-embolic stroke, small-vessel stroke, and high-density lipoprotein (HDL)/low-density
- 97 lipoprotein (LDL) cholesterol levels. We obtained summary SNP-outcome associations with a total
- 98 of 14 human health phenotypes through the MR-BASE platform. Additionally, information regarding
- 99 each outcome trait of interest was extracted (e.g., author/study/consortium name, number of cases
- and controls, publication year, PubMed ID, study population, unit, etc.) and listed in Table 1.

#### 101 **2.3 MR assumptions**

- 102 The assumptions of MR studies can be represented using causal directed acyclic graphs (DAG)
- 103 (Figure 1). In a DAG, the genetic variant  $G_i$  (*j*=1, 2, ..., *J*) and the exposure, *X*, are denoted as  $\gamma_i$ , and
- 104 the association between the genetic variant,  $G_i$ , and the outcome, Y, is denoted as  $\alpha_i$ . Associations
- between a confounding factor (U) and  $G_i$ , X, and Y are denoted as  $\psi_i$ ,  $K_x$ , and  $K_y$ , respectively. In a
- 106 two-sample MR setting, we refer to  $\hat{\gamma}_j$  as an estimate from the *j*<sup>th</sup> SNP-exposure association (with
- 107 variance  $\sigma_{X_j}^2$ ) from sample 1 and  $\hat{\alpha}_j$  as an estimate from the  $j^{\text{th}}$  SNP-outcome association (with
- 108 variance  $\sigma_{Y_i}^2$  from sample 2.

109 Sample 1: 
$$\hat{\gamma}_j = \gamma_j + k_x \varphi_j + \epsilon_{X_j}$$
,  $\operatorname{var}\left(\epsilon_{X_j}\right) = \sigma_{X_j}^2$ 

110 Sample 2: 
$$\hat{\alpha}_j = \alpha_j + k_y \varphi_j + \beta (\gamma_j + k_x \varphi_j) + \epsilon_{Y_j}, \text{ var} (\epsilon_{Y_j}) = \sigma_{Y_j}^2$$

- 111 The genetic variant,  $G_j$ , for valid IVs must satisfy the following three core assumptions; (i) IV1:
- 112  $\gamma_i \neq 0$ , (ii) IV2:  $\varphi_i = 0$ , (iii) IV3:  $\alpha_i = 0$ . Furthermore, MR requires a "NO Measurement Error"
- 113 (NOME) assumption and an Instrument Strength Independent of Direct Effect (InSIDE) assumption.
- 114 It is important to assess the instrument strength to prevent weak instrument bias on MR analysis. We
- evaluated weak instruments with mean F-statistics, and the degree of violation of the NOME

- assumption was quantified using the previously reported  $I^2$  statistic (ranging 0–1) (Bowden et al.,
- 117 2016b). Higher values for  $I^2$  indicate lesser dilution of the causal effect estimate.

#### 118 **2.4 MR methods**

- 119 Using all genetic variants,  $G_i$ , that satisfy the three IV assumptions and the NOME and InSIDE
- 120 assumptions, the causal effect of exposure on the outcome can be consistently estimated from the
- 121 ratio estimates and averaged using an IVW method (Burgess et al., 2013). The IVW estimate is the
- most efficient method when all genetic variants satisfy all three IV assumptions. Cochran's Q
- statistic was used to quantify heterogeneity (Greco et al., 2015; Bowden et al., 2017).
- 124 However, the estimate could be biased if one or more variants are invalid. The weighted median
- 125 method provides valid causal estimates, even if up to 50% of the instruments are invalid. The median
- 126 is unaffected by outliers, making the weighted median estimate insensitive to a pleiotropic genetic
- 127 variant. Causal effects are obtained from the weighted median of the ratio estimates in genetic
- 128 instruments, resulting in smaller standard errors receiving more weight (Bowden et al., 2016a).
- 129 The MR-Egger method allows all SNPs to be used as invalid instruments but requires variants to
- 130 satisfy the InSIDE assumption, enabling estimation of appropriate causal effects in the presence of
- 131 pleiotropic effects (Bowden et al., 2015). This model is suitable for linear regression and the intercept
- 132 term,  $\beta_{0E}$ , is interpreted as the average horizontal pleiotropic effect across the genetic variants
- 133 (Bowden et al., 2015). Rücker's Q' statistic from MR-Egger was used to quantify directional
- heterogeneity (Greco et al., 2015; Bowden et al., 2017). If estimates of  $\beta_{0E}$  equal zero, the MR-Egger
- 135 slope estimate will be the same as the IVW estimate (Burgess and Thompson, 2015). However, when
- 136 the  $I^2$  statistic quantifying the strength of NOME violation for IVs for the MR-Egger method is low,
- 137 a magnitude of regression dilution still occurs. In cases where the NOME assumption is violated, the
- 138 SIMEX method can be used to correct attenuation bias (Bowden et al., 2016b).
- 139 Violation of IV3 (no horizontal pleiotropy) can raise a severe bias in MR analysis. The MR-PRESSO
- 140 test has an advantage over MR-Egger, in that it identifies and removes pleiotropic SNPs. The test
- 141 comprises three parts: 1) the MR-PRESSO global test detects horizontal pleiotropy, 2) the outlier-
- 142 corrected causal estimate corrects for the detected horizontal pleiotropy, and 3) the MR-PRESSO
- 143 distortion test estimates whether the causal estimates differ significantly (P < 0.05) following
- adjustment for the outliers (Verbanck et al., 2018). Therefore, MR-PRESSO results are preferable in
- 145 the presence of a horizontal pleiotropic effect.
- 146 The appropriate methods differ according to the assumptions satisfied, and the most suitable choices
- are presented in Table 2 and 3. The IVW method is the most efficient way to estimate the causal
- 148 effect when all genetic variants are valid instruments (Burgess et al., 2020). In cases where the MR
- 149 assumption of no pleiotropy is not met, the MR-PRESSO test detects possible outliers and provides
- 150 consistent estimates following outlier removal (Burgess and Thompson, 2017). When some genetic
- variants are invalid (<50%), the weighted median approach can be used as an alternative method of
- 152 providing a consistent estimate (Bowden et al., 2016a). By contrast, MR-Egger can obtain a causal
- estimate by correcting directional pleiotropy but has the disadvantage of low power (Bowden et al.,
- 154 2015). If the NOME assumption is violated ( $I^2 < 90\%$ ), the MR-Egger (SIMEX) method would be
- 155 suitable (Bowden et al., 2016b).

#### 156 2.5 Bidirectional MR analysis

- 157 We conducted bidirectional MR analysis to investigate the presence of reverse causality among
- associations between T2D-related traits and outcomes of interest. This was performed by switching
- 159 the exposure and outcomes in opposite directions.

#### 160 **2.6 MR power analysis**

- 161 Power calculations were conducted at https://sb452.shinyapps.io/power/ (Burgess et al., 2020). The
- 162 proportion of variance in the exposure explained by the genetic variants  $(R^2)$  were required for MR
- power analysis, with 0.048 (FPG), 0.017 (2h-PG), and 0.024 (HbA1c) used, respectively. We
- assumed odds ratios (ORs) of 1.1 and 1.2 for binary outcomes and changes in outcomes in standard
- deviation (SD) units per SD change in exposure (0.1 and 0.2) for continuous outcomes. Statistical
- power evaluations at the conservative significance level [0.007 (Bonferroni correction with 7 tests)]
- are plotted in Figure 2.

### 168 **3 Results**

- 169 A total of 34, 7, and 11 genetic variants associated with FPG, 2h-PG, and HbA1c respectively, were
- available as potential instruments from studies included in MAGIC. Each IV set showed genome-
- 171 wide significant ( $P < 5 \times 10^{-8}$ ) associations with T2D-related traits and were not in LD or within
- 172 10,000 kb of an established signal. To investigate IV quality, we generated F-statistics,  $I^2$  values, and
- P-values for Cochran's Q statistic from IVW, Rucker's Q' statistic from MR-Egger, and MR-
- PRESSO global test (Table 4). All instruments used for MR analyses had F-statistics >10, indicating
   no evidence of weak instrument bias. Rejection of the null hypothesis of the Cochran's Q statistic for
- heterogeneity suggested potential pleiotropy in the genetic variants and did not indicate that the
- 177 InSIDE assumptions were invalid. When the pleiotropic effect was present, MR-Egger (with and
- 178 without SIMEX), and MR-PRESSO) were performed rather than using the IVW method. The
- instruments corresponding to FPG satisfied the NOME assumption  $(I^2 > 90)$  but only partially
- 180 satisfied this for HbA1c ( $I^2 > 90$  in only some cases) and did not satisfy this in the case of 2h-PG
- 181  $(I^2 < 90)$ . When the NOME assumption was violated, the results of MR-Egger (SIMEX) were
- 182 generated. Using these IVs, we performed MR analyses for a total of 14 human health phenotypes,
- 183 with all results (3 exposures  $\times$  13 phenotypes  $\times$  5 methods = 185 results) presented in Supplementary
- Table 1. Application of Bonferroni correction to each disease category (0.05/6 = 0.008 for cancer;
- and 0.05/7 = 0.007 for vascular disease) revealed two significant phenotypes (CAD and LDL level)
- associated with T2D-related traits (Table 5). Additionally, we confirmed these relationships through hidiractional and replication analyses (Tables 5 and  $\epsilon$ )
- 187 bidirectional and replication analyses (Tables 5 and 6).

## 188 **3.1 T2D-related traits and cancers**

- 189 We considered FPG, 2h-PG, and HbA1c as exposure traits. For FPG, IVs for lung, ovarian,
- 190 pancreatic, and thyroid cancer satisfied the IV assumptions (F statistics >10,  $I^2 > 90$ , Q-P>0.05), and
- 191 IVW was selected for MR analyses (Table 3). No significant causal association was observed
- between FPG and lung (P=0.721), ovarian (P=0.632), pancreatic (P=0.768), and thyroid (P=0.612)
- 193 cancer. A pleiotropic effect was observed in breast cancer through Q (*P*<0.001), Q' (*P*<0.001)
- statistics, and the MR-PRESSO global test (P<0.001), and MR-PRESSO did not yield significant
- 195 outcomes (P=0.364). The NOME assumption was violated in SC lung cancer ( $l^2 < 90$ ), and the MR-
- 196 Egger (SIMEX) method was used. The MR-Egger (SIMEX) method yielded nominally significant
- 197 (P < 0.05) causal effects (P = 0.032). Furthermore, when 2h-PG was considered an exposure trait, IVs
- 198 for all cancers, except for breast cancer, we found no weak instrument bias (F>10) and no

- heterogeneity (Q-P>0.05, Q'-P>0.05, MR-PRESSO global test-P>0.05), and the IVW method was
- 200 used. However, IVs for breast cancer have a measurement error ( $l^2 < 90$ ), and the MR-Egger (SIMEX)
- 201 method was used. None of the IVs were significant for breast (*P*=0.303), lung (*P*=0.721), SC lung
- 202 (P=0.037), ovarian (P=0.632), pancreatic (P=0.768), and thyroid (P=0.612) cancer. Moreover,
- 203 regarding HbA1c, evidence of violations of IV assumptions for all cancers was obtained (F statistics
- 204 >10, Q-P>0.05, Q'-P>0.05, MR-PRESSO global test-P>0.05), and IVW was applied. No significant
- association was observed between HbA1c and breast (P=0.922), lung (P=0.173), SC lung (P=0.115),
- 206 ovarian (P=0.719), pancreatic (P=0.374), and thyroid (P=0.417) cancer.

For lung, breast, and ovarian cancer, we assumed an OR of 1.2 and we determined the statistical

208 power at between 40% and 70%. The highest power was observed for FPG with the highest  $R^2$ ,

followed by HbA1c and 2h-PG. The estimated statistical power was the highest (>80%) for SC lung

210 cancer for all T2D-related traits owing to a sample size of >100,000 individuals if the standardized

211 effect size is assumed to be same. However, for pancreatic and thyroid cancers, the sample size was

- small (3,835 and 1,080, respectively), thus decreasing the statistical power, indicating the possibility
- 213 of false-negative results. The overall estimated power (Figure 2) revealed no causal effect of FPG,
- 214 2h-PG, and HbA1c on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers (P < 0.008 after
- 215 Bonferroni correction) (Supplementary Table 1).

#### 216 **3.2 T2D-related traits and vascular diseases**

217 All data for vascular diseases were from a sample size of >100,000 patients, giving them a power of 218  $\geq$ 80%, except for detecting an OR of 1.1. We found no causal effect of FPG, 2h-PG, or HbA1c on 219 CKD, HDL level, stroke, or stroke subtype, but two significant causal relationships were observed 220 for FPG with CAD and HbA1c with HDL level. Interestingly, three T2D-related traits used as criteria 221 for diagnosing T2D showed different results for the same phenotype. First, on using FPG as an 222 exposure trait, IVs for CKD and cardio-embolic stroke strongly satisfied the IV assumptions (F 223 statistics >10,  $I^2$  > 90, F statistics >10, O-P>0.05, O'-P>0.05, MR-PRESSO global test-P>0.05), and 224 the IVW approach was selected (Table 2). However, FPG had no causal effects on CKD (P=0.351) 225 and cardio-embolic stroke (P=0.118) were observed, but was nominally significant on small-vessel 226 stroke (P=0.025). In the case of CAD, HDL/LDL cholesterol, and stroke, we found heterogeneity (Q-227 P < 0.05, O'-P < 0.05, MR-PRESSO global test-P < 0.05), and the MR-PRESSO method was applied. 228 Nominally significant results were observed for CAD (MR-PRESSO P=0.045) and non-significant 229 results were observed for HDL cholesterol (P=0.265), LDL cholesterol (P=0.225), and stroke 230 (P=0.135). Second, when 2h-PG was used as an exposure trait, IVs for CKD, stroke, cardio-embolic 231 stroke, and small-vessel stroke strongly satisfied the IV assumptions (F statistics >10, F statistics 232 >10, Q-P>0.05, Q'-P>0.05, MR-PRESSO global test-P>0.05), and the IVW method used. Non-233 significant causal effects were observed for 2h-PG on CKD (P=0.183), stroke (P=0.338), cardio-234 embolic stroke (P=0.530), and small-vessel stroke (P=0.084). In the case of CAD, HDL/LDL cholesterol, all have measurement error ( $I^2 < 90$ ) with heterogeneity ((O-P<0.05, O'-P<0.05, MR-235 236 PRESSO global test-P<0.05), and the MR-Egger (SIMEX) method was used. Non-significant causal 237 effects were observed for 2h-PG on CAD (P=0.301), HDL cholesterol (P=0.074), and LDL 238 cholesterol (P=0.241). Third, when HbA1c was considered an exposure trait, IVs for CKD, HDL 239 cholesterol, stroke, cardio-embolic stroke and small-vessel stroke strongly satisfied the IV 240 assumptions (F statistics >10, Q-P>0.05, Q'-P>0.05, MR-PRESSO global test-P>0.05), and the IVW 241 method was selected. However, no causal effects of HbA1c were observed on CKD (P=0.337), HDL 242 cholesterol (P=0.206), and stroke (P=0.567), but there were nominally significant implications for 243 cardio-embolic stroke (P=0.023) and small-vessel stroke (P=0.046). Owing to the heterogeneity in 244 CAD and LDL cholesterol (Q-P<0.05, Q'-P<0.05, MR-PRESSO global test-P<0.05), the MR-

# PRESSO method was considered, and nominally significant results were obtained for LDL

246 cholesterol (P=0.010), but non-significant for CAD (P=0.069).

247 Significant effects were found for FPG-CAD and HbA1c-LDL cholesterol. Regarding FPG-CAD, all 248 SNP-exposure and SNP-outcome effects are presented in Supplementary Table 2. We found two SNPs significantly correlated with CAD (rs1260326:  $P = 2.40 \times 10^{-5}$ ; and rs7651090:  $P = 1.20 \times 10^{-5}$ 249 250  $10^{-5}$ ); however, given that they exhibited balanced pleiotropy, they were not excluded from the analysis (but were excluded from MR-PRESSO tests). A generated funnel plot showed symmetry, 251 252 indicating heterogeneity due to horizontal pleiotropy (Figure 3A). The associations of the variants with FPG and CAD are shown in a scatter plot with five MR-fitted lines (Figure 3B). Thirty-four 253 254 SNPs were considered instruments, and no weak instrument bias was noted with no violation of 255 NOME assumption, albeit with heterogeneity. Therefore, we assessed the other several sensitivity 256 methods, and observed causal effects of CAD on FPG from the weighted median (P < 0.001). 257 Moreover, we verified that reverse causality did not exist (Table 6). In the replication study using the same IVs and different GWAS data for outcome (PmID = 29212778, N = 296,525, P = European, 258 259 and unit = logOR), there was no weak instrument bias of IVs (N=34, F statistics 43.5) but the 260 heterogeneity assumption was violated (Q-P<0.05, Q'-P<0.05, MR-PRESSO global test-P<0.05). 261 Therefore, MR-PRESSO was selected, and we found that FPG has a positively causal effect on CAD 262 in accordance with the MR-PRESSO method (P = 0.002) (Table 5). On bidirectional MR analysis in the replication study, 83 SNPs were considered instrument variables. Weak instrument bias (F-263 statistics 77.2) and the NOME assumption ( $I^2 = 92.4$ ) were preserved; however, heterogeneity was 264

- 265 observed Q-P<0.05, Q'-P<0.05, MR-PRESSO global test-P<0.05). MR-PRESSO revealed no causal
- effect of CAD on FPG (Table 6).

267 Regarding HbA1c and LDL cholesterol, SNP-exposure and SNP-outcome effects (Supplementary 268 Table 3) indicated that one SNP was significantly correlated with LDL level (rs1800562;  $P=4.42 \times$ 269  $10^{-4}$ ), with this SNP excluded from MR-PRESSO analysis. Figure 4A shows a funnel plot indicating 270 slight non-symmetry, suggesting the presence of heterogeneity due to horizontal pleiotropy. The 271 scatter plot in Figure 4B shows the associations of the variants with HbA1c and LDL level. Eleven 272 SNPs were considered instruments, and no weak instrument bias was noted with no violation of 273 NOME assumption, albeit with heterogeneity. Therefore, we assessed several other sensitivity 274 methods, and observed causal effects of HbA1c on LDL cholesterol from MR-Egger (SIMEX) 275 (P=0.007). In addition, reverse causality was not identified (Table 6). Seventy-four SNPs were 276 considered instruments, and no weak instrument bias was noted (F-statistics 153.9), with no violation 277 of the NOME assumption ( $I^2 = 97.7$ ). However, heterogeneity was observed (Q-P<0.05, Q'-P<0.05, 278 MR-PRESSO global test-P<0.05), and MR-PRESSO revealed no causal effect of LDL cholesterol on 279 HbA1c (P=0.234). Replication analysis using the same IVs and different GWAS data for the 280 outcome-SNP effect (pmID = 28887542, N = 9,961, P = European, unit = mg/dL) revealed no 281 evidence of a weak instrument bias (N=11, F-statistics 77.6) and no heterogeneity (O-P>0.05, O'-P>0.05, MR-PRESSO global test>0.05), but the NOME assumption ( $l^2 = 87.9$ ) was violated. 282 283 Therefore, MR-PRESSO revealed significant results for the causal effect of HbA1c on LDL 284 cholesterol (P=0.032) (Table 5). On bidirectional MR analysis for the replication study, 4 SNPs were 285 considered instrument variables. No weak instrument bias (F-statistics 42.9) and no heterogeneity (O-P>0.05, Q'-P>0.05, MR-PRESSO global test>0.05) were observed; however, a violation of the 286 287 NOME assumption ( $I^2 = 4$ ) was noted. Accordingly, IVW was considered, and no causal effect of

- LDL cholesterol on HbA1c was observed (*P*=0.681) (Table 6).
- 289 4 Discussion

290 In this study, we performed MR analysis of the effect of T2D-related traits on 13 human health 291 phenotypes using GWAS results and data from the MR-BASE registry. In particular, MR analysis 292 was conducted according to three T2D-related criteria (FPG and 2h-PG from the OGTT and HbA1c). 293 MR analyses reduce potential confounding effects and reverse causation, and our results are 294 concurrent with those of previous epidemiological studies. Previous large meta-analyses or 295 systematic reviews of epidemiological studies show that the association between T2D and cancer 296 development is unclear (Tsilidis et al., 2015). Moreover, most epidemiological studies report limitations in findings of T2D-related association with cancers, because they were based on self-297 298 reported health assessments with high specificity (>90%) but low sensitivity (66%) as compared with 299 medical records (Okura et al., 2004). Recently, results of MR analysis indicated no strong evidence 300 supporting a causal relationship between T2D and major solid tumors (stomach, colorectal, liver, 301 pancreas, lung, breast, and prostate) (Goto et al., 2020). Similarly, in the present study, analysis of 302 European data from the MR-Base registry revealed no significant causal effect of T2D-related traits 303 on breast, lung, SC lung, ovarian, pancreatic, and thyroid cancers. Although T2D and cancer share a 304 number of risk factors, such as hyperglycemia, insulin resistance, and dyslipidemia, a relationship 305 between the diseases has not been fully demonstrated (Vigneri et al., 2009). Additionally, studies 306 have reported correlations between hypoglycemic agents and cancer incidence, although these

307 findings remain controversial (Alimova et al., 2009;Currie et al., 2009).

308 In T2D patients, the risk of death from cardiovascular disease increases along with elevated FPG and

309 HbA1c levels, with HbA1c level correlated with microvascular and microvascular complications

310 (Kannel and McGee, 1979;Group, 1998;Okura et al., 2004). Therefore, hyperglycemia represents a

311 strong independent factor for cardiovascular disease, with the risk increasing 2- to 3-fold in men and

312 3- to 4-fold women diagnosed with T2D relative to those without T2D (Kannel and McGee,

1979;Okura et al., 2004). A longitudinal study involving follow-up for 8 years of 2,363 non-diabetic
 adults between the ages of 50 and 75 years reported significant association between 2h-PG and

315 HbA1c levels and an increased risk of death from cardiovascular disease (De Vegt et al., 1999).

316 Moreover, that study identified HbA1c level as not only predictive of improved better mortality from

317 cardiovascular disease relative to FPG and 2h-PG (Park et al., 1996) but also an independent risk

318 factor for atherosclerosis and cardiovascular disease independent of T2D (Nakamura et al.,

319 1993;Kanauchi et al., 2001). In the present study, our findings indicated that vascular disease and

320 LDL level were significantly linked with HbA1c level but not FPG or 2h-PG.

321 We found that different characteristics related to FPG, 2h-PG, and HbA1c differentially influenced

322 IV characteristics. The 2h-PG results from an OGTT represent a standard test for T2D diagnosis.

323 Although 2h-PG testing is more highly sensitive and specific than FPG testing, its low

324 reproducibility is a disadvantage (Peters et al., 1996). The low reproducibility is a consequence of

325 changes in 2-h glucose concentrations for each measurement within a 48-h or 1-week time period in

the same individual. On the other hand, FPG testing is simple and reproducible; however, the

sensitivity for T2D diagnosis is poor, because it does not allow accurate identification of
 hyperglycemia after glucose load (Davidson et al., 1999). HbA1c reflects overall tissue protein

329 glycation and can better reflect the overall biological effect of blood sugar as a 3-month average

330 blood sugar estimate (Peterson et al., 1998); however, HbA1c measurements can be affected by

hemoglobin disease, chronic renal failure, testing methods, and/or specific dosage (Barr et al., 2002).

332 Therefore, these findings suggest that the measurement error associated with SNP-exposure

associations might be large when using any of these criteria. A previous study showed that

334 calculation of the  $l^2$  value confirmed the inadequacy of the NOME assumption due to measurement

error related to 2h-PG testing (Bowden et al., 2016b). Furthermore, reports indicated that the HbA1c

336 level shows less variability in day-to-day within-person variance than FPG (<2% for HbA1c vs. 12–

337 15% for FPG) (Ollerton et al., 1999), and the intra-individual coefficient of variation for FPG (6.4%)

is less than that for 2h-PG (16.7%) (Mooy et al., 1996). Therefore, MR analysis using 2h-PG as an

exposure can be expected to increase the reliability of MR-Egger (SIMEX) findings relative to other

340 methods. In the cases of FPG and HbA1c, IVW results and the sensitivity analysis methods should be 341 examined more broadly.

342 We performed MR analysis using public data from previous large-scale GWAS studies. Producing

in-house genetic data is expensive and requires substantial human resources, making it difficult for

many individual researchers lacking access to appropriate datasets. A two-sample MR approach

345 represents an effective method for discovering novel causal relationships through the use of available

346 large-scale GWAS datasets. Additionally, MR analysis excludes confounding effects by using SNPs

- 347 associated with exposure as genetic instruments, which also reduces the adverse effects of inaccurate
- 348 data on hindering identification of relationships between exposure and outcome.
- 349 The present MR analysis has several limitations. First, some subjects may have overlapped between
- 350 the two data sets with respect to the estimates of instrument-exposure and instrument-outcome, which

351 could lead to inflated type 1 error rates and false-positive findings (Burgess et al., 2016).

352 Furthermore, MR analyses are based on the GWAS. GWAS requires numerous subjects, often in

353 multiple cohorts. Disease definition can differ among different cohorts. Third, we mostly included

354 studies involving a predominantly European population with few individuals of other ancestries

355 (mixed); hence, the present results may not be applicable to other racial backgrounds. Nevertheless,

356 the present results support the results of previous epidemiology studies and promote further studies in 357 this field.

#### 358 **5** Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

#### 361 6 Author Contributions

J.J. analyzed and interpreted the results and wrote the manuscript. S.W. and S.L. designed the study.All authors revised this paper critically for important intellectual content.

#### 364 **7 Funding**

365 This study was supported by the National Research Foundation of Korea (2017M3A9F3046543).

#### 366 8 Acknowledgements

367 None

#### 368 9 Data Availability Statement

- 369 All datasets presented in this study are included in the supplementary material and available at
- 370 <u>https://www.mrbase.org/</u> and <u>https://gwas.mrcieu.ac.uk/</u>.

371

#### 372 **10 References**

- Alimova, I.N., Liu, B., Fan, Z., Edgerton, S.M., Dillon, T., Lind, S.E., and Thor, A.D. (2009).
   Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. *Cell Cycle* 8, 909-915.
- 376 Association, A.D. (2010). Standards of medical care in diabetes—2010. *Diabetes Care* 33, S11-S61.
- Barr, R.G., Nathan, D.M., Meigs, J.B., and Singer, D.E. (2002). Tests of glycemia for the diagnosis
  of type 2 diabetes mellitus. *Ann. Int. Med.* 137, 263-272.
- Bax, J.J., Young, L.H., Frye, R.L., Bonow, R.O., Steinberg, H.O., and Barrett, E.J. (2007). Screening
   for coronary artery disease in patients with diabetes. *Diabetes Care* 30, 2729-2736.
- Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid
   instruments: effect estimation and bias detection through Egger regression. *Int. J. Epidemiol.* 44, 512-525.
- Bowden, J., Davey Smith, G., Haycock, P.C., and Burgess, S. (2016a). Consistent estimation in
   Mendelian randomization with some invalid instruments using a weighted median estimator.
   *Genet. Epidemiol.* 40, 304-314.
- Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N.A., and Thompson, J.R.
  (2016b). Assessing the suitability of summary data for two-sample Mendelian randomization
  analyses using MR-Egger regression: the role of the I 2 statistic. *Int. J. Epidemiol.* 45, 19611974.
- Bowden, J., Del Greco M, F., Minelli, C., Davey Smith, G., Sheehan, N., & Thompson, J. (2017). A
   framework for the investigation of pleiotropy in two sample summary data Mendelian
   randomization. *Stat. Med.* 36(11), 1783-1802.
- Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian randomization analysis with
   multiple genetic variants using summarized data. *Genet. Epidemiol.* 37, 658-665.
- Burgess, S., Davies, N.M., and Thompson, S.G. (2016). Bias due to participant overlap in
   two□ sample Mendelian randomization. *Genet. Epidemiol.* 40, 597-608.
- Burgess, S., Smith, G.D., Davies, N.M., Dudbridge, F., Gill, D., Glymour, M.M., Hartwig, F.P.,
   Holmes, M.V., Minelli, C., and Relton, C.L. (2020). Guidelines for performing Mendelian
   randomization investigations. *Wellcome Open Research* 4, 186.
- Burgess, S., and Thompson, S.G. (2015). *Mendelian randomization: methods for using genetic variants in causal estimation*. CRC Press.
- Burgess, S., and Thompson, S.G. (2017). Interpreting findings from Mendelian randomization using
   the MR-Egger method. *Eur. J. Epidemiol.* 32, 377-389.
- 405 Collaboration, E.R.F. (2011). Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N.* 406 *Engl. J. Med.* 364, 829-841.
- 407 Currie, C., Poole, C., and Gale, E. (2009). The influence of glucose-lowering therapies on cancer risk
  408 in type 2 diabetes. *Diabetologia* 52, 1766-1777.

409 Davidson, M.B., Schriger, D.L., Peters, A.L., and Lorber, B. (1999). Relationship between fasting
410 plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2
411 diabetes using new diagnostic criteria. *JAMA* 281, 1203-1210.

412 413 414	De Vegt, F., Dekker, J., Ruhe, H., Stehouwer, C., Nijpels, G., Bouter, L., and Heine, R. (1999). Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. <i>Diabetologia</i> 42, 926-931.
415 416	Gavin Iii, J.R., Alberti, K., Davidson, M.B., and Defronzo, R.A. (1997). Report of the expert committee on the diagnosis and classification of diabetes mellitus. <i>Diabetes Care</i> 20, 1183.
417 418	Gleissner, C.A., Galkina, E., Nadler, J.L., and Ley, K. (2007). Mechanisms by which diabetes increases cardiovascular disease. <i>Drug Discov. Today: Dis. Mech.</i> 4, 131-140.
419 420 421	Goto, A., Yamaji, T., Sawada, N., Momozawa, Y., Kamatani, Y., Kubo, M., Shimazu, T., Inoue, M., Noda, M., and Tsugane, S. (2020). Diabetes and cancer risk: A Mendelian randomization study. <i>nt. J. Cancer</i> 146, 712-719.
422 423 424	Greco M, F. D., Minelli, C., Sheehan, N. A., & Thompson, J. R. (2015). Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. <i>Stat. Med.</i> 34(21), 2926-2940.
425 426 427	Group, U.P.D.S. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). <i>The Lancet</i> 352, 837-853.
428 429 430	Hemani, G., Zheng, J., Wade, K.H., Laurin, C., Elsworth, B., Burgess, S., Bowden, J., Langdon, R., Tan, V., and Yarmolinsky, J. (2016). MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations. <i>BioRxiv</i> , 078972.
431 432 433	Johnson, J., Carstensen, B., Witte, D., Bowker, S., Lipscombe, L., Renehan, A., Diabetes, and Consortium, C.R. (2012). Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. <i>Diabetologia</i> 55, 1607-1618.
434 435	Kanauchi, M., Tsujimoto, N., and Hashimoto, T. (2001). Advanced glycation end products in nondiabetic patients with coronary artery disease. <i>Diabetes Care</i> 24, 1620-1623.
436 437	Kannel, W.B., and Mcgee, D.L. (1979). Diabetes and cardiovascular disease: the Framingham study. <i>JAMA</i> 241, 2035-2038.
438 439	Laakso, M. (1999). Hyperglycemia and cardiovascular disease in type 2 diabetes. <i>Diabetes</i> 48, 937-942.
440 441 442 443	Mooy, J., Grootenhuis, P., De Vries, H., Kostense, P., Popp-Snijders, C., Bouter, L., and Heine, R. (1996). Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. <i>Diabetologia</i> 39, 298-305.
444 445 446 447	Nakamura, Y., Horii, Y., Nishino, T., Shiiki, H., Sakaguchi, Y., Kagoshima, T., Dohi, K., Makita, Z., Vlassara, H., and Bucala, R. (1993). Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. <i>Am. J. Pathol.</i> 143, 1649.
448 449	Nathan, D., Turgeon, H., and Regan, S. (2007). Relationship between glycated haemoglobin levels and mean glucose levels over time. <i>Diabetologia</i> 50, 2239-2244.
450 451	Nathan, D.M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., and Heine, R.J. (2008). Translating the A1C assay into estimated average glucose values. <i>Diabetes Care</i> 31, 1473-1478.
452	Nesto, R. (2001). CHD: a major burden in type 2 diabetes. Acta Diabetol. 38, S3-S8.

453 454 455 456	Okura, Y., Urban, L.H., Mahoney, D.W., Jacobsen, S.J., and Rodeheffer, R.J. (2004). Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. <i>J. Clin. Epidemiol.</i> 57, 1096-1103.
457 458 459	Ollerton, R.L., Playle, R., Ahmed, K., Dunstan, F.D., Luzio, S.D., and Owens, D.R. (1999). Day-to- day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. <i>Diabetes Care</i> 22, 394-398.
460 461 462	Park, S., Barrett-Connor, E., Wingard, D.L., Shan, J., and Edelstein, S. (1996). GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. <i>Diabetes Care</i> 19, 450-456.
463 464 465	Peters, A.L., Davidson, M.B., Schriger, D.L., and Hasselblad, V. (1996). A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. <i>JAMA</i> 276, 1246-1252.
466 467 468	<ul> <li>Peterson, K.P., Pavlovich, J.G., Goldstein, D., Little, R., England, J., and Peterson, C.M. (1998).</li> <li>What is hemoglobin A1c? An analysis of glycated hemoglobins by electrospray ionization mass spectrometry. <i>Clin. Chem.</i> 44, 1951-1958.</li> </ul>
469 470 471 472	Scott, R.A., Lagou, V., Welch, R.P., Wheeler, E., Montasser, M.E., Mägi, R., Strawbridge, R.J., Rehnberg, E., Gustafsson, S., and Kanoni, S. (2012). Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. <i>Nat. Genet.</i> 44, 991.
473 474	Tsilidis, K.K., Kasimis, J.C., Lopez, D.S., Ntzani, E.E., and Ioannidis, J.P. (2015). Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. <i>BMJ</i> . 350, g7607.
475 476 477	Verbanck, M., Chen, CY., Neale, B., and Do, R. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. <i>Nat. Genet.</i> 50, 693-698.
478 479	Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009). Diabetes and cancer. EndocrRelat. Cancer 16, 1103-1123.
480 481 482 483	Young, L.H., Frans, J.T., Chyun, D.A., Davey, J.A., Barrett, E.J., Taillefer, R., Heller, G.V., Iskandrian, A.E., Wittlin, S.D., and Filipchuk, N. (2009). Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. <i>JAMA</i> 301, 1547-1555.
484	
485	
486	
487	
488	
489 100	
470	

Category	Trait	Consortium/ First author	PubMed ID	Unit	No. of cases	No. of controls	No. of SNPs	Population
1. Cancer								
	Breast cancer	BCAC	25751625	LogOR	15,748	18,084	13,011,123	European
	Lung cancer	ILCCO	24880342	LogOR	11,348	15,861	8,945,893	European
	Lung cancer (SC)	ILCCO	24880342	LogOR	3,275	150,038	8,893,750	European
	Ovarian cancer	OCAC	28346442	LogOR	1,366	40,941	11,403,952	European
	Pancreatic cancer	PanScan1	19648918	LogOR	1,896	1,939	521,863	European
	Thyroid cancer	Kohler A	23894154	LogOR	649	431	572,028	European
2. Vascular disease								
	CAD	VanderHarst P	29212778	LogOR	122,733	424,528	7,934,254	European
	CKD	CKDGen	26831199	LogOR	12,385	104,780	2,191,877	Mixed
	HDL cholesterol	GLGC	24097068	SD		187,167	2,447,442	Mixed
	LDL cholesterol	GLGC	24097068	SD		173,082	2,437,752	Mixed
	Stroke	Malik R	29531354	LogOR	40,585	406,111	7,633,440	European
	(Cardio-embolic)	Malik R	29531354	LogOR	7,193	406,111	8,271,294	European
	(Small-vessel)	Malik R	29531354	LogOR	5,386	192,662	6,150,261	European

#### 491 **Table 1.** Description of data from MR-Base based on the phenotype

492 SC, squamous cell; SD, standard deviation; CKD, chronic kidney disease; CAD, coronary artery disease; LDL, low-density lipoprotein; HDL, high 493 density lipoprotein; logOR, log odds ratio.

#### 494 **Table 2.** Recommended MR methods by assumption of IVs

No weak IVs (F>10)	NOME	No Heterogeneity	<b>Recommended Methods</b>
Satisfied	Satisfied	Satisfied	IVW
Satisfied	Satisfied	At least one violated	→Table 2
Satisfied	Violated	Satisfied	IVW
Satisfied	Violated	At least one violated	MR-Egger (SIMEX)
Violated	Satisfied	Satisfied	Weighted median
Violated	Satisfied	At least one violated	→Table 2
Violated	Violated	Satisfied	MR-Egger (SIMEX)
Violated	Violated	At least one violated	MR-Egger (SIMEX)
simulation extrapolatio	n;		, inverse variance weighted, i
Table 3. Recommende	d MR method	s by heterogeneity test	

Q test <sup>†</sup>	Q' test <sup>†</sup>	MR-PRESSO global test‡	<b>Recommended Methods</b>
			IVW
$\checkmark$	$\checkmark$		MR-Egger
	$\checkmark$		IVW
$\checkmark$			MR-Egger
		1	IVW, if there is no weak IV
		v	MR- MR-PRESSO, otherwise
$\checkmark$	$\checkmark$	$\checkmark$	MR-PRESSO
	/	/	IVW, if there is no weak IV (F>10)
	$\checkmark$	v	MR- MR-PRESSO, ow (F<10)
$\checkmark$		$\checkmark$	MR-Egger, MR-PRESSO

- 517  $\checkmark$ : significant (heterogeneity exists)
- <sup>†</sup>Greco et al., 2015; Bowden et al., 2017
- <sup>±</sup> Verbanck et al., 2018
- 520 IV, instrument variable; IVW, inverse-variance-weighted; MR-PRESSO, MR-Pleiotropy RESidual Sum and
- 521 Outlier
- 522
- 523
- 524

		FPG (	$R^2=0.0$	048)		2h-PG	$G(R^2 =$	0.017)		HbA1c	$(R^2 = 0$	.024)
	Ν	F	I <sup>2</sup> (%)	Q Q' RSS	N	F	I <sup>2</sup> (%)	Q Q' RSS	N	F	<i>I</i> <sup>2</sup> (%)	Q Q' RSS
1. Cancer												
Breast cancer	34	130.5	96.8	< 0.001	7	43.5	29.8	< 0.001	11	77.6	92.2	0.110
				< 0.001				0.019				0.249
				< 0.001				0.023				0.371
Lung cancer	33	133.0	97.3	0.182	7	43.5	36.2	0.322	11	77.6	87.6	0.021
				0.183				0.397				0.063
				0.211				0.258				0.089
SC lung cancer	33	43.5	40.1	0.599	7	43.5	40.1	0.875	11	77.6	87.9	0.198
				0.553				0.786				0.154
				0.477				0.913				0.216
Ovarian cancer	33	133.5	97.4	0.530	7	43.5	28.1	0.323	11	77.6	87.8	0.243
				0.490				0.224				0.334
				0.412				0.362				0.298
Pancreatic cancer	25	111.7	96.4	0.138	6	45.0	31.8	0.710	8	82.1	90.9	0.239
				0.122				0.594				0.186
				0.199				0.642				0.214
Thyroid cancer	27	144.9	97.9	0.183	5	47.4	21.9	0.434	9	81.7	91.2	0.882
				0.248				0.703				0.899
				0.275				0.621				0.885
2. Cardiovascular	disea	se										
CAD	34	130.5	97.3	< 0.001	7	43.5	23.0	< 0.001	11	77.6	88.0	0.002
				< 0.001				< 0.001				0.014
				< 0.001				< 0.001				0.018
CKD	32	135.8	97.4	0.106	7	43.5	29.1	0.482	10	82.1	86.5	0.632
				0.114				0.451				0.548
				0.151	_			0.395				0.421
HDL cholesterol	34	130.5	97.3	< 0.001	7	43.5	2.4	< 0.001	11	77.6	90.9	0.545
				< 0.001				< 0.001				0.589
		1000		< 0.001	_	40 -		< 0.001				0.436
LDL cholesterol	34	130.8	97.2	< 0.001	1	43.5	5.7	< 0.001	11	77.6	91.1	< 0.001
				< 0.001				< 0.001				< 0.001
G. 1	2.4	100 5	07.0	< 0.001	-	40.5	20.0	< 0.001			060	< 0.001
Stroke	34	130.5	97.3	< 0.001	1	43.5	39.9	0.069	11	77.6	86.0	0.075
				< 0.001				0.051				0.084
	2.4	100 5	07.4	< 0.001	-	10.1	25.2	0.067			00 <b>न</b>	0.092
(Cardio-embolic)	34	130.5	97.4	0.498	/	43.4	35.2	0.733	11	//.6	88.7	0.255
				0.649				0.611				0.247
(0 11 1)	22	105.0	07.6	0.557	-	10 5		0.694	10	76.00	06.6	0.275
(Small-vessel)	32	135.8	97.6	0.038	1	43.5	55.6	0.675	10	/6.88	80.6	0.556
				0.130				0.636				0.522
				0.199				0.645				0.512

525 **Table 4.** Assumption check for instrumental variables

526F, F-statistic; Q, P-value for the Q-test from IVW; Q', P-value for the Q'-test from MR-Egger; RSS, P-value527for MR-PRESSO global test, SC, squamous cell; CKD, chronic kidney disease; CAD, coronary artery disease;528LDL, low-density lipoprotein; HDL, high-density lipoprotein; FPG, fasting plasma glucose; 2h-PG, 2-h529plasmaglucose;HbA1,hemoglobinA1c.

#### Table 5. Significant results from MR and replication analyses

	<b>D</b>	0.4				Original study			Replication study	
No.	Exposure	Outcome	MR method	Parameter	Ν	Estimate (95% CI)	Р	Ν	Estimate (95% CI)	Р
1	FPG	CAD	IVW	Estimate	34	0.21 (0.05, 0.37)	0.012	34	0.14 (-0.02, 0.29)	0.078
			MR Egger	Intercept		0.00 (-0.01, 0.01)	0.530		0.01 (0.00, 0.02)	0.090
				Slope		0.13 (-0.18, 0.43)	0.426		-0.07 (-0.36, 0.22)	0.626
			MR Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.443		0.00 (-0.01, 0.01)	0.769
				Slope		0.22 (0.06, 0.39)	0.014		0.144 (-0.02, 0.30)	0.087
			MR-PRESSO (O-C)	Estimate	32	0.18 (0.01, 0.35)	0.045	28	0.19 (0.07, 0.32)	0.002
			Weighted median	Estimate		0.29 (0.14, 0.45)	< 0.001		0.20 (0.07, 0.34)	0.003
2	HbA1c	LDL cholesterol	IVW	Estimate	11	0.23 (0.05, 0.41)	0.015	10	0.15 (-0.31, 0.61)	0.521
			MR Egger	Intercept		-0.01 (-0.03, 0.01)	0.281		-0.05 (-0.08, -0.01)	0.004
				Slope		0.45 (0.01, 0.88)	0.046		0.14 (0.39, 1.89)	0.003
			MR Egger (SIMEX)	Intercept		-0.01 (-0.02, 0.00)	0.053		0.00 (-0.02, 0.02)	0.780
				Slope		0.27 (0.11, 0.44)	0.007		0.16 (-0.33, 0.65)	0.539
			MR-PRESSO (O-C)	Estimate	10	0.14 (0.03, 0.25)	0.010	9	0.38 (0.03, 0.72)	0.032
			Weighted median	Estimate		0.15 (0.03, 0.26)	0.012		0.44 (0.03, 0.84)	0.036

MR, Mendalian randomization; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; Hb1Ac, hemoglobin A1c.

#### 544 **Table 6.** Significant results from bidirectional MR analysis

	U		5							
NI-	No Exposure Outcome					Original study			Replication study	
INO.	Exposure	Outcome	<b>MR</b> methods	parameter	Ν	Estimate (95% CI)	Р	Ν	Estimate (95% CI)	Р
1	CAD	FPG	IVW	Estimate	30	0.00 (-0.02, 0.02)	0.873	83	0.00 (-0.01, 0.01)	0.834
			MR Egger	Intercept		0.00 (-0.01, 0.01)	0.352		0.00 (-0.01, 0.01)	0.813
				Slope		-0.02 (-0.06, 0.02)	0.437		0.00 (-0.02, 0.03)	0.906
			MR Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.435		0.00 (-0.01, 0.01)	0.907
				Slope		0.01 (-0.01, 0.02)	0.781		0.00 (-0.01, 0.01)	0.844
			MR-PRESSO (O-C)	Estimate	29	0.00 (-0.02, 0.02)	0.877		No outlier	
			Weighted median	Estimate		0.01 (-0.01, 0.03)	0.186		0.00 (-0.01, 0.01)	0.834
2	LDL	HbA1c	IVW	Estimate	74	0.02 (-0.01, 0.05)	0.202	4	-0.01 (-0.04, 0.03)	0.681
	cholesterol		MR Egger	Intercept		0.00 (-0.01, 0.01)	0.263		0.00 (-0.02, 0.02)	0.796
				Slope		-0.01 (-0.06, 0.05)	0.859		-0.02 (-0.13, 0.09)	0.719
			MR Egger (SIMEX)	Intercept		0.02 (-0.01, 0.00)	0.056		0.00 (-0.01, 0.01)	0.513
				Slope		0.02 (-0.01, 0.05)	0.158		-0.02 (-0.03, 0.01)	0.548
			MR-PRESSO (O-C)	Estimate	71	0.02 (-0.01, 0.04)	0.234		Not enough IVs	
			Weighted median	Estimate		-0.01 (-0.03, 0.03)	0.911		-0.02 (-0.04, 0.02)	0.376

545 MR, Mendalian randomization; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and

546 Outlier (outlier-correction); LDL, low-density lipoprotein; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; Hb1Ac, 547 hemoglobin A1c.

#### 548 11 Figure Legends

- 549 Figure 1. Causal directed acyclic graph for MR analysis.
- 550 MR, Mendalian randomization.
- 551 Figure 2. Statistical power evaluations of MR analyses based on the T2D-diagnosis criteria. (A) FPG, (B)
- 2h-PG, and (C) HbA1c. We used a conservative significance threshold of P < 0.007 with Bonferroni
- 553 correction using 7 of testing.
- MR, Mendalian randomization; T2D, type 2 diabetes; FPG, fasting plasma glucose; 2h-PG, 2-h plasma
   glucose; HbA1c, hemoglobin A1c; OR, odds ratio; SD, standard deviation.
- **Figure 3.** MR analysis of the effect of FPG on CAD. (A) Funnel plot displaying individual causal
- effect estimates for FPG on CAD. Dots representing the estimated causal effect for each IV. (**B**) The
- association between the effect size estimates on the FPG (X-axis) and CAD (Y-axis) for all SNPs that
- served as IVs.
- 560 FPG, fasting plasma glucose; CAD, coronary artery disease; IV, instrumental variable; SNP, single-
- 561 nucleotide polymorphism; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual
- 562 Sum and Outlier (outlier-correction).
- 563 **Figure 4.** MR analysis of the effect of HbA1c on LDL levels. (A) Funnel plot displaying individual
- causal effect estimates for HbA1c on LDL levels. Dots represent the estimated causal effect for each
- 565 IV. (**B**) The relationship between the effect size estimates on HbA1c (X-axis) and LDL level (Y-axis)
- 566 for all SNPs that served as IVs.
- 567 MR, Mendalian randomization; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; IV,
- 568 instrumental variable; SNP, single-nucleotide polymorphism; SIMEX, simulation extrapolation;
- 569 PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction).





2hr Plasma Glucose











# Supplementary Material

Chr	CNID	ΕA	OA		SNP Exposur	e	SNP	Outcome	
Chir	SINF	EA	UA	Beta	SE	Р	Beta	SE	Р
1	rs2779116	Т	С	0.024	0.004	2.75	0.013	0.006	0.106
2	rs552976	G	А	0.029	0.003	8.16	0.002	0.004	0.424
6	rs1800562	А	G	-0.064	0.007	2.59	-0.062	0.008	4.42
7	rs1799884	Т	С	0.038	0.004	1.45	-0.002	0.005	0.988
8	rs4737009	А	G	0.027	0.004	6.12	0.003	0.004	0.574
8	rs6474359	С	Т	-0.060	0.011	1.18	-0.026	0.011	0.030
10	rs16926246	Т	С	-0.089	0.006	3.11	-0.018	0.007	0.001
11	rs1387153	Т	С	0.026	0.004	3.96	-0.003	0.004	0.490
13	rs7998202	G	А	0.031	0.005	5.24	-0.005	0.008	0.804
17	rs1046896	Т	С	0.035	0.003	1.58	0.002	0.004	0.528
22	rs855791	G	А	-0.027	0.004	2.74	-0.010	0.004	0.003

Supplementary Table 1. Instrument variables for HbA1c and LDL cholesterol.

Chr, chromosome; EA, effect allele; OA, other allele; SE, standard error; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; SNP, single-nucleotid e polymorphism.

Supplementary Table 2. MR results for T2D-related traits on cancers and vascular disease.



			FPG			2h-PG			HbA1c	,
Trait and MR methods	Parameter	Ν	Estimate (95% CI)	Р	N	Estimate (95% CI)	Р	Ν	Estimate (95% CI)	Р
1. Cancer										
Breast cancer										
IVW	Estimate	34	-0.05 (-0.28, 0.18)	0.671	7	0.16 (-0.06, 0.37)	0.151	11	-0.01 (-0.28, 0.25)	0.922
MR-Egger	Intercept		0.00 (-0.01, 0.01)	0.537		-0.09 (-0.16, -0.01)	0.028		0.02 (0.00, 0.04)	0.067
	Slope		-0.18 (-0.65, 0.29)	0.456		1.08 (0.24, 1.92)	0.012		-0.46(-0.98, 0.07)	0.092
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.996		0.00 (-0.02, 0.03)	0.941		0.01 (-0.01, 0.02)	0.301
	Slope		-0.05 (-0.29, 0.19)	0.679		0.15 (-0.11, 0.42)	0.303		-0.04 (-0.30, 0.23)	0.800
MR-PRESSO (O-C)	Estimate	33	-0.10 (-0.32, 0.36)	0.364	5	0.16 (-0.01, 0.34)	0.068		No outlier	
Weighted median	Estimate		-0.20 (-0.44, 0.04)	0.094		0.21 (0.06, 0.36)	0.008		-0.03 (-0.32, 0.29)	0.842
Lung cancer										
IVW	Estimate	33	0.05 (-0.22, 0.32)	0.721	7	-0.13 (-0.32, 0.06)	0.188	11	0.36 (-0.16, 0.88)	0.173
MR-Egger	Intercept		0.01 (-0.01, 0.02)	0.330		-0.06 (-0.15, 0.03)	0.182		0.04 (-0.01, 0.08)	0.102
	Slope		-0.17 (-0.68, 0.35)	0.523		0.48 (-0.43, 1.39)	0.301		-0.50 (-1.65, 0.64)	0.389
MR-Egger (SIMEX)	Intercept		-0.01 (-0.02, 0.01)	0.148		0.00 (-0.02, 0.03)	0.795		0.00 (-0.02, 0.02)	0.898
	Slope		0.14 (-0.19, 0.35)	0.351		-0.15 (-0.39, 0.09)	0.286		0.37 (-0.19, 0.94)	0.233
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	_		No outlier	_
Weighted median	Estimate		-0.03 (-0.37, 0.32)	0.880		-0.08 (-0.32, 0.16)	0.494		0.04 (-0.47, 0.54)	0.886
SC lung cancer										
IVW	Estimate	33	0.39 (0.02, 0.76)	0.037	7	-0.19 (-0.46, 0.08)	0.161	11	0.36 (-0.16, 0.88)	0.173
MR-Egger	Intercept		0.00 (-0.02, 0.02)	0.792		0.00 (-0.13, 0.13)	0.968		0.04 (-0.01, 0.08)	0.102
	Slope		0.31 (-0.38, 1.00)	0.376		-0.17 (-1.52, 1.19)	0.811		-0.50 (-1.65, 0.64)	0.389
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.480		0.01 (-0.01, 0.03)	0.307		-0.01 (-0.04, 0.02)	0.453
	Slope		0.41 (0.05, 0.77)	0.032		-0.26 (-0.46, -0.06)	0.052		0.58 (-0.09, 1.26)	0.127
MR-PRESSO (O-C)	Estimate		No outlier	_		No outlier	—		No outlier	
Weighted median	Estimate		0.36 (-0.17, 0.88)	0.180		-0.16 (-0.50, 0.17)	0.341		0.04 (-0.47, 0.54)	0.886
Ovarian cancer										
IVW	Estimate	33	-0.14(-0.68, 0.42)	0.632	7	0.14 (-0.29, 0.58)	0.526	11	0.16 (-0.73, 1.06)	0.719
MR-Egger	Intercept		0.08 (-0.96, 1.13)	0.882		-0.01 (-0.24, 0.21)	0.905		0.06 (-0.02, 0.13)	0.142
	Slope		-0.01 (-0.04, 0.02)	0.637		0.28 (-2.12, 2.69)	0.817		-1.19 (-3.18, 0.80)	0.242
MR-Egger (SIMEX)	Intercept		-0.01 (-0.02, 0.01)	0.426		-0.04 (-0.07, -0.01)	0.044		0.03 (0.00, 0.06)	0.089
	Slope		-0.11 (-0.66, 0.44)	0.705		0.39 (0.03, 0.75)	0.087		-0.03(-0.85, 0.79)	0.948
MR-PRESSO (O-C)	Estimate		No outlier	—		No outlier	—		No outlier	—
Weighted median	Estimate		-0.46 (-1.33, 0.40)	0.293		-0.01 (-0.54, 0.53)	0.980		0.08 (-1.05, 1.21)	0.886
Pancreatic cancer										
IVW	Estimate	25	-0.14 (-1.07, 0.79)	0.768	6	-0.01 (-0.50, 0.49)	0.973	8	0.53 (-0.64, 1.71)	0.374



MR-Egger	Intercept		0.02 (-0.03, 0.06)	0.537		-0.04(-0.27, 0.18)	0.702		0.03 (-0.08, 0.14)	0.592
	Slope		-0.64 (-2.49, 1.21)	0.497		0.45 (-1.94, 2.84)	0.713		-0.11 (-2.78, 2.56)	0.934
MR-Egger (SIMEX)	Intercept		-0.01 (-0.04, 0.02)	0.455		0.00 (-0.01, 0.05)	0.874		0.01 (-0.04, 0.06)	0.792
	Slope		-0.07 (-1.03, 0.89)	0.883		0.02 (-0.53, 0.57)	0.942		0.51 (-0.77, 1.79)	0.464
MR-PRESSO (O-C)	Estimate		No outlier	_		No outlier	_		No outlier	
Weighted median	Estimate		-0.81 (-2.01, 0.38)	0.184		-0.05 (-0.67, 0.57)	0.883		0.46 (-0.87, 1.78)	0.500
Thyroid cancer										
ĨVW	Estimate	27	-0.34(-1.67, 0.98)	0.612	5	-0.53 (-1.43, 0.38)	0.257	9	0.68 (-0.97, 2.33)	0.417
MR-Egger	Intercept		0.06(-0.01, 0.13)	0.116		0.32(-0.08, 0.73)	0.122		-0.07(-0.21, 0.07)	0.349
20	Slope		-1.89(-4.22, 0.43)	0.110		-3.97(-8.43, 0.49)	0.081		2.30 (-1.47, 6.07)	0.231
MR-Egger (SIMEX)	Intercept		0.00(-0.05, 0.04)	0.918		0.06 (-0.04, 0.17)	0.333		-0.02(-0.07, 0.02)	0.344
	Slope		-0.34 (-1.73, 1.05)	0.641		-0.98(-2.12, 0.16)	0.192		0.89(-0.30, 2.09)	0.186
MR-PRESSO (O-C)	Estimate		No outlier	_		No outlier	_		No outlier	_
Weighted median	Estimate		-1.14 (-2.73, 0.44)	0.157		-0.80(-1.98, 0.38)	0.184		1.19 (-0.89, 3.28)	0.262
2. Cardiovascular diseas	e		,							
CAD										
IVW	Estimate	34	0.21 (0.05, 0.37)	0.012	7	0.12 (-0.06, 0.31)	0.183	11	0.24 (0.02, 0.46)	0.031
MR-Egger	Intercept		0.00(-0.01, 0.01)	0.530		0.05(-0.03, 0.14)	0.231		0.02(-0.01, 0.03)	0.078
20	Slope		0.13 (-0.18, 0.43)	0.426		-0.42(-1.32, 0.48)	0.365		-0.14 (-0.60, 0.33)	0.569
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.443		0.00 (-0.02, 0.02)	0.833		0.00 (-0.01, 0.01)	0.762
	Slope		0.22 (0.06, 0.39)	0.014		0.14 (-0.09, 0.37)	0.301		0.23 (-0.01, 0.47)	0.085
MR-PRESSO (O-C)	Estimate	32	0.18 (0.01, 0.35)	0.045	5	0.21 (0.13, 0.29)	< 0.001	10	0.19 (-0.01, 0.39)	0.069
Weighted median	Estimate		0.29 (0.14, 0.45)	< 0.001		0.21 (0.10, 0.31)	< 0.001		0.09 (-0.11, 0.30)	0.369
CKD										
IVW	Estimate	32	0.12(-0.13, 0.36)	0.351	7	0.08 (-0.07, 0.23)	0.301	10	0.16 (-0.16, 0.47)	0.337
MR-Egger	Intercept		-0.01(-0.02, 0.01)	0.281		0.01 (-0.06, 0.09)	0.760		-0.01 (-0.03, 0.02)	0.697
	Slope		0.33(-0.13, 0.78)	0.159		-0.04 (-0.83, 0.75)	0.916		0.29 (-0.48, 1.07)	0.455
MR-Egger (SIMEX)	Intercept		0.01 (-0.01, 0.01)	0.109		0.01 (-0.01, 0.02)	0.555		0.00 (-0.01, 0.01)	0.785
	Slope		0.08 (-0.16, 0.32)	0.496		0.05 (-0.13, 0.23)	0.601		0.17 (-0.14, 0.49)	0.315
MR-PRESSO (O-C)	Estimate		No outlier	_		No outlier	_		No outlier	
Weighted median	Estimate		0.17(-0.12, 0.46)	0.252		0.09 (-0.10, 0.28)	0.359		0.24 (-0.17, 0.65)	0.243
HDL cholesterol										
IVW	Estimate	34	-0.08(-0.08, 0.25)	0.320	7	0.07 (-0.08, 0.23)	0.342	11	0.19 (-0.11, 0.51)	0.206
MR-Egger	Intercept		0.01 (0.00, 0.02)	0.219		0.02 (-0.06, 0.09)	0.680		0.03 (0.00, 0.06)	0.049
20	Slope		-0.08 (-0.39, 0.23)	0.606		-0.10 (-0.94, 0.74)	0.817		-0.37 (-1.01, 0.27)	0.252
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.728		-0.01 (-0.03, 0.00)	0.064		0.01 (-0.01, 0.02)	0.227
· /	Slope		0.09 (-0.08, 0.26)	0.259		0.15 (0.02, 0.28)	0.074		0.17 (-0.12, 0.47)	0.282
MR-PRESSO (O-C)	Estimate	28	0.04 (-0.03, 0.09)	0.265	5	0.04 (-0.02, 0.11)	0.206		No outlier	_



Weighted median	Estimate		0.03 (-0.05, 0.10)	0.514		0.01 (-0.05, 0.06)	0.833		0.07 (-0.32, 0.46)	0.729
LDL cholesterol										
IVW	Estimate	34	0.02 (-0.16, 0.20)	0.807	7	0.04 (-0.11, 0.19)	0.626	11	0.23 (0.05, 0.41)	0.015
MR-Egger	Intercept		0.01 (-0.01, 0.01)	0.394		0.02 (-0.05, 0.09)	0.566		-0.01 (-0.03, 0.01)	0.281
	Slope		-0.10 (-0.44, 0.24)	0.551		-0.19 (-1.00, 0.61)	0.636		0.45 (0.01, 0.88)	0.046
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.341		-0.01 (-0.03, 0.01)	0.143		-0.01 (-0.02, 0.00)	0.053
	Slope		0.04 (-0.14, 0.22)	0.695		0.10 (-0.05, 0.25)	0.241		0.27 (0.11, 0.44)	0.007
MR-PRESSO (O-C)	Estimate	27	0.04 (-0.03, 0.11)	0.225	5	0.06 (0.01, 0.11)	0.033	10	0.14 (0.03, 0.25)	0.010
Weighted median	Estimate		-0.01 (-0.08, 0.07)	0.890		0.04 (-0.02, 0.10)	0.214		0.15 (0.03, 0.26)	0.012
Stroke										
IVW	Estimate	34	0.15 (-0.03, 0.33)	0.104	7	0.06 (-0.06, 0.17)	0.338	11	-0.06 (-0.27, 0.15)	0.567
MR-Egger	Intercept		0.01 (0.00, 0.02)	0.005		-0.02 (-0.07, 0.04)	0.579		0.01 (-0.01, 0.03)	0.308
	Slope		-0.24 (-0.56, 0.08)	0.137		0.22 (-0.37, 0.81)	0.467		-0.30 (-0.81, 0.21)	0.244
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.174		0.00 (-0.01, 0.01)	0.930		0.00 (-0.01, 0.01)	0.396
	Slope		0.17 (-0.01, 0.35)	0.078		0.06 (-0.09, 0.21)	0.469		-0.09 (-0.31, 0.13)	0.451
MR-PRESSO (O-C)	Estimate	33	0.13 (-0.04, 0.31)	0.135		0.05 (-0.06, 0.17)	0.338		No outlier	
Weighted median	Estimate		0.02 (-0.16, 0.19)	0.835		0.04 (-0.08, 0.16)	0.506		-0.15 (-0.38, 0.08)	0.205
Stroke (cardio-embolic)										
IVW	Estimate	34	0.22 (-0.05, 0.48)	0.118	7	0.06 (-0.13, 0.26)	0.530	11	-0.51 (-0.94, -0.04)	0.023
MR-Egger	Intercept		0.01 (0.00, 0.03)	0.047		0.00 (-0.09, 0.09)	0.988		0.02 (-0.02, 0.06)	0.369
	Slope		-0.23 (-0.74, 0.29)	0.387		0.07 (-0.91, 1.05)	0.889		-0.93 (-1.96, 0.09)	0.076
MR-Egger (SIMEX)	Intercept		0.00 (-0.01, 0.01)	0.266		-0.01 (-0.02, 0.01)	0.383		0.01 (-0.01, 0.02)	0.403
	Slope		-0.03 (-0.03, 0.51)	0.094		0.11 (-0.07, 0.29)	0.294		-0.56 (-1.01, -0.10)	0.039
MR-PRESSO (O-C)	Estimate		No outlier			No outlier			No outlier	
Weighted median	Estimate		0.03 (-0.36, 0.41)	0.889		0.01 (-0.24, 0.25)	0.937		-0.55 (-1.09, -0.02)	0.045
Stroke (small-vessel)										
IVW	Estimate	32	0.34 (0.04, 0.64)	0.025	7	0.16 (-0.02, 0.33)	0.084	10	0.37 (0.01, 0.73)	0.046
MR-Egger	Intercept		0.02 (0.01, 0.04)	0.016		0.03 (-0.05, 0.11)	0.443		-0.01 (-0.05, 0.02)	0.422
	Slope		-0.22 (-0.75, 0.32)	0.427		-0.16 (-1.00, 0.67)	0.700		0.71 (-0.19, 1.61)	0.124
MR-Egger (SIMEX)	Intercept		-0.01 (-0.01, 0.01)	0.209		0.00 (-0.02, 0.02)	0.744		0.00 (-0.02, 0.01)	0.551
	Slope		0.37 (0.08, 0.68)	0.020		0.11 (-0.07, 0.34	0.255		0.42 (0.04, 0.79)	0.063
MR-PRESSO (O-C)	Estimate		No outlier			No outlier			No outlier	
Weighted median	Estimate		0.16 (-0.24, 0.55)	0.435		0.12 (-0.10, 0.35)	0.294		0.46 (-0.03, 0.94)	0.065

MR, Mendalian randomization; T2D, type 2 diabetes; IVW, inverse-variance-weighted; SIMEX, simulation extrapolation; PRESSO (O-C), Pleiotropy RESidual Sum and Outlier (outlier-correction); SC, squamous cell; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CKD, chronic kidney disease; CAD, coronary artery disease; CI, confidence interval; FPG, fasting plasma glucose; 2h-PG, 2-h plasma glucose; Hb1Ac, hemoglobin A1c.



#### **SNP** Exposure **SNP** Outcome Chr **SNP** EA OA Beta SE Р Beta SE Р 1 rs17712208 А Т 0.051 0.007 3.22 0.002 0.019 0.920 Т $2.4 \times 10^{-5}$ 2 rs1260326 С 0.029 0.002 2.17 0.007 -0.0302 rs479661 Α G -0.0190.003 8.56 -0.0140.009 0.150 2 rs560887 С Т 0.071 0.003 0.023 0.008 0.002 1.40 3 G -0.0230.017 rs11708067 А 0.003 1.30 -0.0200.008 3 rs11715915 Т С -0.0120.002 4.90 -0.0210.008 0.005 3 С Т -0.0260.003 0.007 0.520 rs1280 8.56 0.010 3 $1.2 \times 10^{-5}$ rs7651090 G А 0.013 0.002 1.75 0.033 0.007 5 Т С 0.018 0.002 0.003 0.007 0.660 rs4869272 1.02 6 rs9368222 А С 0.014 0.002 1.00 -0.0050.008 0.560 7 Т С 0.031 0.003 -0.0060.009 0.500 rs17168486 3.17 7 Т rs2191349 G 0.029 0.002 1.28 0.011 0.007 0.130 7 С Т 0.005 0.500 rs6943153 -0.0150.002 1.63 0.007 7 С Т rs6975024 0.061 0.003 2.88 0.027 0.009 0.003 7 Т rs882020 С 0.021 0.003 0.015 0.010 0.150 3.04 8 rs11558471 G А -0.0290.002 7.80 -0.0030.008 0.709 8 rs983309 G Т -0.0260.003 6.29 0.019 0.011 0.072 9 С Т rs10811661 -0.0240.003 5.65 -0.0080.009 0.410 9 С rs10814916 А 0.016 0.002 2.26 -0.0100.007 0.130 9 rs16913693 G Т -0.0430.007 -0.0040.021 0.830 3.51 9 rs3829109 Α G -0.0170.003 1.13 -0.0250.008 0.002 10 rs11195502 Т С -0.0320.004 1.97 -0.0230.012 0.048 С 10 rs7903146 Т 0.022 0.002 2.71 0.017 0.008 0.027 С G 0.078 0.003 1.00 0.007 0.008 0.370 11 rs10830963 11 rs11603334 Α G -0.0190.003 1.12 0.008 0.010 0.390 G 11 rs11607883 А -0.0210.002 6.32 0.000 0.007 0.960 11 rs174576 С -0.0200.002 1.18 -0.0170.007 0.019 А 11 rs749067 С Т -0.0170.002 6.12 0.001 0.007 0.940 12 G 0.013 0.002 0.007 0.008 rs10747083 А 7.57 0.320 13 G 0.002 0.008 0.008 0.320 rs11619319 А 0.020 1.33 Т 14 rs3783347 G -0.0170.003 -0.0200.008 0.020 1.32 rs4502156 С Т -0.0220.002 0.001 0.007 0.890 15 1.38 20 rs6072275 Α G 0.016 0.003 1.66 -0.0160.010 0.110 G 2.49 0.018 20 rs6113722 А -0.0350.005 -0.0120.500

#### Supplementary Table 3. Instrument variables for FPG and CAD.

FPG, fasting plasma glucose; CAD, coronary artery disease; Chr, chromosome; EA, effect allele; OA, other allele; SE, standard error; LDL, low–density lipoprotein; HbA1, hemoglobin A1c; SNP, single-nucleotide pol ymorphism.